EMPACT-MI analysis “reassuring” on use of empagliflozin in patients with poor kidney function
Empagliflozin preserved kidney function and was safe to initiate in heart attack patients, findings of a secondary analysis of the EMPACT-MI trial, published in...
Modelling suggests early CKD screening and diagnosis could cut dialysis use
New analysis of the IMPACT CKD study suggests that targeted screening, diagnosis and improved access to care for patients with chronic kidney disease (CKD)...
SeaStar Medical reaches interim enrolment target for NEUTRALIZE-AKI pivotal trial
SeaStar Medical Holding has announced that it has successfully reached the halfway point in the NEUTRALIZE-AKI pivotal clinical trial, enabling a per protocol prespecified...
CX 2025: “Robust” patency seen at six months in FLEX First AV registry
Six-month outcomes of the FLEX First arteriovenous (AV) registry, assessing the safety and efficacy of the Flex vessel prep (VP) system (VentureMed) in combination...
